Substituted Cyclopentenes for Glaucoma Intraocular Pressure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension, such as those using eicosanoids and their derivatives, are inadequate in effectively managing intraocular pressure and preventing vision loss in patients, particularly for primary open-angle glaucoma.
Innovation Solution
The development of well-defined substituted cyclopentenes, which are administered topically as ophthalmically acceptable compositions, to reduce intraocular pressure and treat glaucoma by facilitating the drainage of aqueous humor and thereby lowering intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but the treatment is inadequate for effectively managing intraocular pressure and preventing vision loss in all patients
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostaglandin analogs through substitution at specific positions (e.g., 15-position substitutions with groups like —CH2OH, —CF3, aryl, or heteroaryl) to create compounds with enhanced and differentiated pharmacological properties, thereby improving effectiveness and adaptability across different patient populations
2Reliability
If conventional eicosanoid derivatives are used, then some intraocular pressure reduction is achieved, but the treatment fails to effectively prevent vision loss in primary open-angle glaucoma patients
Solution Approach 1:
The patent employs composite material principles by creating substituted cyclopentene structures that combine the core prostaglandin framework with additional functional groups (such as aryl, heteroaryl, and hydroxyl substituents), resulting in compounds with synergistic effects that enhance both therapeutic efficacy and vision protection capabilities
Data Source
AI summary
Disclosed herein are compounds having a formula:or a pharmaceutically acceptable salt thereof, as well as therapeutic methods, medicaments, and compositions related thereto.